Biotech | April 04, 2025
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Increases speed to market for drug developers working on nucleic acid therapeutics
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Subscribe To Our Newsletter & Stay Updated
